Trust Co. of Vermont Purchases New Shares in Chemed Co. (NYSE:CHE)

Trust Co. of Vermont acquired a new stake in Chemed Co. (NYSE:CHE) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 65 shares of the company’s stock, valued at approximately $34,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. raised its stake in shares of Chemed by 72.5% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 840 shares of the company’s stock worth $445,000 after acquiring an additional 353 shares during the last quarter. Fifth Third Wealth Advisors LLC raised its position in Chemed by 22.9% in the 4th quarter. Fifth Third Wealth Advisors LLC now owns 584 shares of the company’s stock worth $309,000 after purchasing an additional 109 shares during the last quarter. Bright Rock Capital Management LLC acquired a new position in Chemed during the 4th quarter worth $1,060,000. Signal Advisors Wealth LLC boosted its position in Chemed by 60.7% in the 4th quarter. Signal Advisors Wealth LLC now owns 4,995 shares of the company’s stock valued at $2,647,000 after buying an additional 1,886 shares during the last quarter. Finally, Sugarloaf Wealth Management LLC increased its stake in shares of Chemed by 21.9% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 7,150 shares of the company’s stock valued at $3,788,000 after buying an additional 1,285 shares during the period. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed Stock Up 0.4 %

CHE stock opened at $555.01 on Tuesday. Chemed Co. has a twelve month low of $512.12 and a twelve month high of $654.62. The company has a market cap of $8.35 billion, a P/E ratio of 28.04, a price-to-earnings-growth ratio of 2.04 and a beta of 0.47. The business’s fifty day moving average is $545.17 and its 200-day moving average is $562.92.

Chemed (NYSE:CHE) last released its earnings results on Tuesday, October 29th. The company reported $5.64 earnings per share for the quarter, missing the consensus estimate of $5.76 by ($0.12). The company had revenue of $606.18 million during the quarter, compared to analyst estimates of $612.22 million. Chemed had a net margin of 12.69% and a return on equity of 27.86%. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company posted $5.32 EPS. Research analysts anticipate that Chemed Co. will post 21.43 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 6th. Investors of record on Monday, November 18th were paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 0.36%. The ex-dividend date was Monday, November 18th. Chemed’s payout ratio is 10.11%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CHE. Royal Bank of Canada cut their price target on Chemed from $697.00 to $633.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. StockNews.com upgraded shares of Chemed from a “hold” rating to a “buy” rating in a research report on Saturday, November 30th.

Insider Activity at Chemed

In other Chemed news, VP Brian C. Judkins bought 145 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was purchased at an average cost of $519.50 per share, with a total value of $75,327.50. Following the completion of the purchase, the vice president now owns 1,678 shares in the company, valued at approximately $871,721. The trade was a 9.46 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $572.77, for a total value of $1,145,540.00. Following the sale, the chief executive officer now directly owns 101,735 shares in the company, valued at approximately $58,270,755.95. This represents a 1.93 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 3.32% of the company’s stock.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.